Q2'23 NOI +15% y-o-y, -1% vs ABGSCe Value changes -4.
Redeye expresses concern over the termination of the partnership between Kontigo Care and the Finnis...
Dovre revised guidance down due to larger-than-expected challenges in the Finnish wind power constru...
Redeye comments on Freemelt ahead of its Q2-results (due 10 Aug).
Redeye updates its estimates and valuation range following yesterday's announcement of Enea's strate...
Ahead of Doro's Q2 report scheduled for release on July 14, Redeye revises its forecasts, with minor...
Redeye welcomes Enea’s announced cost savings program.
Q2 report due 9 August We expect GM pressure and churn to stay high.
Inför Beijer Almas Q2-rapport förväntar vi oss stigande försäljning och en rörelsemarginal vid 14%.
Redeye comments on the order from Ayar Labs, which it believes to be only the start of a significant...
With the establishment of the first commercial agreement with IDFC Bank in India, Crunchfish’s Digit...
Redeye expect Invisio to continue to perform strong in Q2 2023 (results due 21 July) where the order...
Redeye comments on the outcome of Binero’s rights issue, which brings in a total of cSEK0.
Efter en lång tid av strävan har Hexicon nu en långsiktig finansieringslösning på plats.
Q2 report due on Friday 14 July Estimates fine-tuned Q2e EBIT margin of 6.
Försening i tidslinjen... Egetis meddelade under onsdagskvällen att de förskjuter den planerade tids...
S2Medical har tagit fram en ny strategi där resurser läggs på befintliga produkter vilket ska bidra ...
Redeye was glad to see that Moberg Pharma received the EU approval within the indicated time frame.
Buys wooden furniture & components manufacturer Hedlunda Adds ~46% to PF EBITDA for '23e 3.
Candles aviserade i början av 2023 om en renodling av verksamheten samtidigt som tillväxtmålet om mi...
